Mild Neurocognitive DisorderDeep MINDNCT07038798
Deep rTMS for Mild Neurocognitive Disorder in Older Adults
A study testing Brainsway H1-Coil Deep TMS System, Brainsway H4-Coil Deep TMS System and Brainsway H7-Coil Deep TMS System in people with Mild Neurocognitive Disorder, run by St. Joseph's Healthcare Hamilton at 1 site in Canada.
Trial summary
This study aims to: (1) assess the feasibility and tolerability of three deep transcranial magnetic stimulation (dTMS) coils H1, H4, and H7 in older adults with mild neurocognitive disorder (mild NCD); and (2) evaluate changes in cognition through neuropsychological testing, brain activity through EEG, and mood and… Read more about this study
- Who is it for?
- Ages 60 to 90 years
- Conditions the study is for
- Mild Neurocognitive Disorder
- What is being tested?
- Brainsway H1-Coil Deep TMS System, Brainsway H4-Coil Deep TMS System and Brainsway H7-Coil Deep TMS System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteCanada
- Study dates
- 26 Aug 2025to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 60 - 90 years old
- Able to provide informed consent to participate in the study
- Subjective concern of mild decline in cognitive function over the past year
- Mild impairment in cognitive performance
- Preserved independence in everyday activities
- Independently mobile (e.g., participants must be able to get in and out of a chair on their own)
- Participants will be required to be on stable dosages of other psychotropic medications for at least 4 weeks prior to screening
Who cannot join
- Currently receiving treatment or subjective need for treatment for bipolar I or II disorder; psychotic disorder
- Active suicidal behavior
- Severe depression and/or anxiety
- Other neurological or psychiatric disorders accounting for the cognitive deficits
- Impairment in basic and/or instrumental activities of daily living
- Substance use disorder (other than tobacco use disorder) in the past 3 months before entering the study
Show all 11Show fewer
- Traditional contraindications to rTMS: Intracranial or metal implants in the head or nearby regions, excluding the mouth, that cannot be safely removed; History of epilepsy or seizures; Active unstable medical condition (recent laboratory and neuroimaging alterations, delirium); Pacemaker and/or implantable cardioverter-defibrillators; current use of bupropion, treatment with equivalent benzodiazepine dose to lorazepam >2 mg/day
- People with severe literacy, visual, or hearing issues that affect the ability to engage in the interviews
- People with recurring migraines or headaches (weekly or more)
- Frequent dizziness/vertigo
- Individuals residing beyond the borders of the Greater Hamilton Area and its neighbouring vicinities
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L9C 0E3
Jane De Jesus, BSc, 905-522-1155, dejesuj@mcmaster.ca
Dante Duarte, MD, MSc, PhD, 905 522-1155 ext. 36782, duartedante@mcmaster.ca
About this study
Official title: Feasibility and Tolerability of Deep Repetitive Transcranial Magnetic Stimulation for Mild Neurocognitive Disorder in Older Adults: A Pilot Study (DeepMIND)
This study aims to: (1) assess the feasibility and tolerability of three deep transcranial magnetic stimulation (dTMS) coils H1, H4, and H7 in older adults with mild neurocognitive disorder (mild NCD); and (2) evaluate changes in cognition through neuropsychological testing, brain activity through EEG, and mood and sleep through self-report questionnaires. Participants will be assigned to one of three arms: H1- coil vs. H4-coil vs. H7-coil, and all participants will complete assessments examining dTMS side effects, mental health symptoms, and cognition. EEG, questionnaires, and CNS vital signs will be measured at baseline, midpoint (after 10th session- before dTMS treatment on visit 11), and end point, as well as follow up. Collectively, the study will address the absolute and differential feasibility and tolerability of the H1, H4 and H7 coils to provide preliminary data for a future randomized controlled trial comparing this novel intervention to a sham stimulation (placebo) control.
Read the detailed description
Transcranial magnetic stimulation (TMS) is a non-invasive therapeutic technique used to stimulate regions of the brain using magnetic pulses. Repeated TMS delivers sequences of pulses for multiple days in a row and is an approved treatment for several psychiatric conditions. Deep TMS (dTMS) is a new technique that uses modified magnetic Hesed coils (H-coils) to stimulate deeper regions of the brain and has been FDA- and Health Canada-approved for major depressive disorder (MDD), obsessive-compulsive disorder, smoking cessation, and anxious-depression in adults. While some research has demonstrated potential benefits of dTMS for cognitive impairment in Alzheimer's disease and other neurodegenerative conditions, its feasibility and tolerability in mild neurocognitive disorder (mild NCD) remain largely unexplored. This innovative pilot study will examine the feasibility and tolerability (side effects, impacts on mental health and cognition), of three dTMS coils (H1, H4 and H7) in older adults with mild NCD. The H1-coil targets bilateral prefrontal cortices, the H4-coil targets the insula and prefrontal cortex, and the H7-coil targets the medial prefrontal cortex and anterior cingulate cortex. These regions are known to be involved in memory, attention, mood regulation, and executive functioning and implicated in mild NCD.
Using an open-label, parallel design, participants aged 60-90 will be assigned to one of three dTMS coils and will complete a six-week course of 20 stimulation sessions (five sessions per week for the first two weeks, three sessions per week for the next two, and two sessions per week for the final two weeks). Each session will include a brief cognitive "priming" task designed to engage brain regions prior to stimulation. In addition to monitoring side effects and retention rates, the study will measure participants' cognitive performance through neuropsychological testing and assess brain function changes through electroencephalogram (EEG) recordings. EEG will be conducted at baseline, midpoint (after 10th session- before dTMS treatment on visit 11), and end point, as well as follow up to capture changes in neural activity and connectivity. This study will lay critical groundwork for a larger, future randomized controlled trial.
- Conditions
- Mild Neurocognitive Disorder
- Being tested
- Brainsway H1-Coil Deep TMS System, Brainsway H4-Coil Deep TMS System, Brainsway H7-Coil Deep TMS System
- Keywords
- Mild Neurocognitive Disorder, Mild NCD, Mild Cognitive Impairment, Deep Transcranial Magnetic Stimulation, deep TMS, dTMS, H coil, H-coil, H1-coil, H4-coil, H7-coil
- Medical subject headings
- Neurocognitive Disorders, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Brainsway H1-Coil Deep TMS SystemDevice
Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H1-coil.
Brainsway H4-Coil Deep TMS SystemDevice
Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H4-coil.
Brainsway H7-Coil Deep TMS SystemDevice
Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H7-coil.
| Study group | Role | What they receive |
|---|---|---|
| Active H1-coil dTMS treatment | Experimental | This arm will receive dTMS treatment through active H1-coil. Receives: Device: Brainsway H1-Coil Deep TMS System |
| Active H4-coil dTMS treatment | Experimental | This arm will receive dTMS treatment through active H4-coil. Receives: Device: Brainsway H4-Coil Deep TMS System |
| Active H7-coil dTMS treatment | Experimental | This arm will receive dTMS treatment through active H7-coil. Receives: Device: Brainsway H7-Coil Deep TMS System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility criteria 1: Protocol completion
Percentage of intervention sessions completed
Measured: 6 weeks
Feasibility criteria 2: Retention rate
Percentage of participants who complete study once enrolled
Measured: 6 weeks
Feasibility criteria 3: Screening rates and capacity
Number of participants (n) screened; n enrolled as a percentage of n screened monthly
Measured: 6 weeks
Feasibility criteria 4: Recruitment rate and capacity
Total number of participants recruited and enrolled per month.
Measured: 6 weeks
Feasibility criteria 5: Duration of intervention and assessment processes
Compared to estimated times, the actual mean times (in min) from start to finish for each dTMS intervention session and mean time (in hours) from start to finish for each visit.
Measured: 6 weeks
Feasibility criteria 6: Safety of H-coil dTMS treatment
Total number of adverse events reported during the treatment sessions assessed by the Side Effects Questionnaire for dTMS (custom-developed for study). At each dTMS stimulation session, participants will complete a questionnaire to evaluate potential adverse effects of dTMS (headache, neck pain, itching and redness at the site of stimulation) according to a 4-point scale.
Measured: 6 weeks
Tolerability of H-coil dTMS treatment
Percentage of participants withdrawn or terminated following enrollment due to adverse events
Measured: 6 weeks
Secondary outcomes (12)
Changes from baseline on the Everyday Memory Questionnaire (EMQ)
The Everyday Memory Questionnaire (EMQ) is a 28-item self-report tool, that will be used to assess the frequency and impact of everyday memory problems. It will be measured at baseline (V1), midpoint (after 10th session - before deep TMS treatment on V11) and end point, as well as follow-up.
Measured: 6 weeks + one-month follow-up
Changes from baseline in Neurocognitive Performance measured by the CNS Vital Signs Test Battery
The CNS Vital Signs is the name of a standardized computerized neurocognitive test battery and not a set of physiological vital signs like heart rate or blood pressure. The assessments within CNS Vital Signs are cognitive domains such as memory, executive function, processing speed, etc., not physiological measurements.
It will be measured at baseline (V1), midpoint (after 10th session - before deep TMS treatment on V11) and end point, as well as follow-up.
Measured: 6 weeks + one-month follow-up
Change from baseline on the Hamilton Depression Rating Scale- 24 item (HDRS-24).
Symptoms of depression will be assessed with the HDRS- 24 item (a 24-item depression checklist) at multiple visits: at baseline (V1), midpoint (after 10th session - before deep TMS treatment on V11) and end point, as well as follow-up.
Measured: 6 weeks + one-month follow-up
Change from baseline on the General Anxiety Disorder- 7 item (GAD-7)
Symptoms of anxiety will be assessed using this 7-item questionnaire at baseline (V1), midpoint (after 10th session - before deep TMS treatment on V11) and end point, as well as follow-up. Scores of 0-4 indicate minimal anxiety; 5-9: mild anxiety; 10-14: moderate anxiety; and 15 or greater: severe anxiety.
Measured: 6 weeks + one-month follow-up
Change from baseline on the Pittsburgh Sleeping Quality Index (PSQI)
Sleep will be monitored and assessed using the Pittsburgh Sleeping Quality Index (PSQI) at baseline (V1), midpoint (after 10th session - before deep TMS treatment on V11) and end point, as well as follow-up.
Measured: 6 weeks + one-month follow-up
Change from baseline on the Patient Health Questionnaire (PHQ - Somatic Symptoms)
Somatic symptoms will be evaluated using the Patient Health Questionnaire (PHQ) somatic inventory at baseline (V1), midpoint (after 10th session - before deep TMS treatment on V11) and end point, as well as follow-up.
Measured: 6 weeks + one-month follow-up
Changes from baseline on the Multifactorial Memory Questionnaire (MMQ)
The Mulitfactorial Memorial Questionnaire (MMQ) is a self-report tool to evaluate three distinct aspects of memory: satisfaction with memory (MMQ-Satisfaction), the frequency of memory lapses (MMQ-Ability), and the use of memory strategies (MMQ-Strategy). It will be measured at baseline (V1), midpoint (after 10th session - before deep TMS treatment on V11) and end point, as well as follow-up.
Measured: 6 weeks + one-month follow-up
Changes from baseline in resting-state EEG
Using electroencephalography (EEG), we will assess alpha, theta and gamma rhythms in fronto-temporo-parietal region, including assessment of connectivity and coherence. We will additionally measure cross-frequency coupling named theta (4-8Hz)-gamma (>25Hz) phase-amplitude coupling (PAC). We will also investigate phase synchronization in upper theta frequency band between prefrontal and temporal areas. Changes in these EEG parameters will be correlated with changes in mood severity and cognitive status, with a focus on working memory improvements. EEG will be performed before dTMS sessions at baseline (V1), midpoint (after 10th session - before deep TMS treatment on V11) and end point, as well as follow-up, by using a wireless dry electrode portable EEG system (CGX Quick 20r). Resting state connectivity, coherence, PAC, and synchronization assessed by EEG will use standardized data processing pipelines in EEG Lab
Measured: 6 weeks + one-month follow-up
Changes from baseline in WHO Quality of Life Questionnaire - BREF (WHOQOL-BREF)
WHOQOL-BREF will measure quality of life in physical, psychological and social domains. This will be measured at baseline (V1), midpoint (after 10th session - before deep TMS treatment on V11) and end point, as well as follow-up.
Measured: 6 weeks + one-month follow-up
Changes from baseline Patient Global Impression of Improvement (PGI-I)
The PGI-I is a single-item global assessment scale used to measure the patient's perceived improvement following an intervention or treatment. This will be measured at midpoint (V11), end of the treatment (V20) and at one-month follow-up.
Measured: 6 weeks + one-month follow-up
Changes from baseline on the Monetary Choice Questionnaire (Delay Discounting)
Delay discounting task which assess propensity to devalue future rewards by asking participants to choose between an immediate small monetary amount and a delayed larger monetary amount. Rewards are hypothetical. This will be measured at baseline (V1), midpoint (after 10th session - before deep TMS treatment on V11) and end point, as well as follow-up
Measured: 6 weeks + one-month follow-up
Changes from baseline in blood biomarkers
Quantity specific biomarkers associated with neurodegeneration {Brain-derived neurotrophic factor (BDNF), Beta-amyloid ratio (Aβ1-42/Aβ1-40 ratio), Phosphorylated Tau 217 (pTAU-217), Neurofilmament light chain (NfL), Cytokines (IGF-1, VEGF, TGF-β1, MCP-1, IL-18)}, will be analyzed using immunoassays, including enzyme-linked immunosorbent assays (ELISA) and single molecular array (SIMOA) technology. These will be measured at baseline (V1) and at one-month follow-up.
Measured: 6 weeks + one-month follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2025
- Study start26 Aug 2025
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mild Neurocognitive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- One way three-group between-subjects open-label, parallel-arm design
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- St. Joseph's Healthcare Hamilton
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dante Duarte, St. Joseph's Healthcare Hamilton
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07038798
- Sponsor's protocol ID
- 18440
- Acronym
- Deep MIND
- Status last verified
- May 2025
- First submitted
- 2 Jun 2025
- Last updated
- 6 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility and Tolerability of Deep Repetitive Transcranial Magnetic Stimulation for Mild Neurocognitive Disorder in Older Adults: A Pilot Study (DeepMIND)
- ClinicalTrials.gov ID
- NCT07038798
- Acronym / sponsor ID
- Deep MIND / 18440
- Conditions
- Mild Neurocognitive Disorder
- Keywords
- Mild Neurocognitive Disorder, Mild NCD, Mild Cognitive Impairment, Deep Transcranial Magnetic Stimulation, deep TMS, dTMS, H coil, H-coil
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- St. Joseph's Healthcare HamiltonUniversity, hospital or other
- Study start
- 26 Aug 2025 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 26 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to: (1) assess the feasibility and tolerability of three deep transcranial magnetic stimulation (dTMS) coils H1, H4, and H7 in older adults with mild neurocognitive disorder (mild NCD); and (2) evaluate changes in cognition through neuropsychological testing, brain activity through EEG, and mood and sleep through self-report questionnaires. Participants will be assigned to one of three arms: H1- coil vs. H4-coil vs. H7-coil, and all participants will complete assessments examining dTMS side effects, mental health symptoms, and cognition. EEG, questionnaires, and CNS vital signs will be measured at baseline, midpoint (after 10th session- before dTMS treatment on visit 11), and end point, as well as follow up. Collectively, the study will address the absolute and differential feasibility and tolerability of the H1, H4 and H7 coils to provide preliminary data for a future randomized controlled trial comparing this novel intervention to a sham stimulation (placebo) control.
Detailed description
Transcranial magnetic stimulation (TMS) is a non-invasive therapeutic technique used to stimulate regions of the brain using magnetic pulses. Repeated TMS delivers sequences of pulses for multiple days in a row and is an approved treatment for several psychiatric conditions. Deep TMS (dTMS) is a new technique that uses modified magnetic Hesed coils (H-coils) to stimulate deeper regions of the brain and has been FDA- and Health Canada-approved for major depressive disorder (MDD), obsessive-compulsive disorder, smoking cessation, and anxious-depression in adults. While some research has demonstrated potential benefits of dTMS for cognitive impairment in Alzheimer's disease and other neurodegenerative conditions, its feasibility and tolerability in mild neurocognitive disorder (mild NCD) remain largely unexplored. This innovative pilot study will examine the feasibility and tolerability (side effects, impacts on mental health and cognition), of three dTMS coils (H1, H4 and H7) in older adults with mild NCD. The H1-coil targets bilateral prefrontal cortices, the H4-coil targets the insula and prefrontal cortex, and the H7-coil targets the medial prefrontal cortex and anterior cingulate cortex. These regions are known to be involved in memory, attention, mood regulation, and executive functioning and implicated in mild NCD.
Using an open-label, parallel design, participants aged 60-90 will be assigned to one of three dTMS coils and will complete a six-week course of 20 stimulation sessions (five sessions per week for the first two weeks, three sessions per week for the next two, and two sessions per week for the final two weeks). Each session will include a brief cognitive "priming" task designed to engage brain regions prior to stimulation. In addition to monitoring side effects and retention rates, the study will measure participants' cognitive performance through neuropsychological testing and assess brain function changes through electroencephalogram (EEG) recordings. EEG will be conducted at baseline, midpoint (after 10th session- before dTMS treatment on visit 11), and end point, as well as follow up to capture changes in neural activity and connectivity. This study will lay critical groundwork for a larger, future randomized controlled trial.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- One way three-group between-subjects open-label, parallel-arm design
| Arm | Type | Receives |
|---|---|---|
| Active H1-coil dTMS treatment | Experimental | Device: Brainsway H1-Coil Deep TMS SystemThis arm will receive dTMS treatment through active H1-coil. |
| Active H4-coil dTMS treatment | Experimental | Device: Brainsway H4-Coil Deep TMS SystemThis arm will receive dTMS treatment through active H4-coil. |
| Active H7-coil dTMS treatment | Experimental | Device: Brainsway H7-Coil Deep TMS SystemThis arm will receive dTMS treatment through active H7-coil. |
Who may qualify
- Ages
- 60 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- 60 - 90 years old
- Able to provide informed consent to participate in the study
- Subjective concern of mild decline in cognitive function over the past year
- Mild impairment in cognitive performance
- Preserved independence in everyday activities
Key exclusion criteria (11 listed)
- Currently receiving treatment or subjective need for treatment for bipolar I or II disorder; psychotic disorder
- Active suicidal behavior
- Severe depression and/or anxiety
- Other neurological or psychiatric disorders accounting for the cognitive deficits
- Impairment in basic and/or instrumental activities of daily living
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Brainsway H1-Coil Deep TMS SystemParticipants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H1-coil. | Device | Active H1-coil dTMS treatment |
| Brainsway H4-Coil Deep TMS SystemParticipants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H4-coil. | Device | Active H4-coil dTMS treatment |
| Brainsway H7-Coil Deep TMS SystemParticipants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H7-coil. | Device | Active H7-coil dTMS treatment |
Primary outcome
Feasibility criteria 1: Protocol completion
Time frame: 6 weeks
Percentage of intervention sessions completed
Feasibility criteria 2: Retention rate
Time frame: 6 weeks
Percentage of participants who complete study once enrolled
Feasibility criteria 3: Screening rates and capacity
Time frame: 6 weeks
Number of participants (n) screened; n enrolled as a percentage of n screened monthly
Feasibility criteria 4: Recruitment rate and capacity
Time frame: 6 weeks
Total number of participants recruited and enrolled per month.
Feasibility criteria 5: Duration of intervention and assessment processes
Time frame: 6 weeks
Compared to estimated times, the actual mean times (in min) from start to finish for each dTMS intervention session and mean time (in hours) from start to finish for each visit.
Feasibility criteria 6: Safety of H-coil dTMS treatment
Time frame: 6 weeks
Total number of adverse events reported during the treatment sessions assessed by the Side Effects Questionnaire for dTMS (custom-developed for study). At each dTMS stimulation session, participants will complete a questionnaire to evaluate potential adverse effects of dTMS (headache, neck pain, itching and redness at the site of stimulation) according to a 4-point scale.
Tolerability of H-coil dTMS treatment
Time frame: 6 weeks
Percentage of participants withdrawn or terminated following enrollment due to adverse events
12 secondary outcomes
Changes from baseline on the Everyday Memory Questionnaire (EMQ)
Time frame: 6 weeks + one-month follow-up
Changes from baseline in Neurocognitive Performance measured by the CNS Vital Signs Test Battery
Time frame: 6 weeks + one-month follow-up
Change from baseline on the Hamilton Depression Rating Scale- 24 item (HDRS-24).
Time frame: 6 weeks + one-month follow-up
Change from baseline on the General Anxiety Disorder- 7 item (GAD-7)
Time frame: 6 weeks + one-month follow-up
Change from baseline on the Pittsburgh Sleeping Quality Index (PSQI)
Time frame: 6 weeks + one-month follow-up
Change from baseline on the Patient Health Questionnaire (PHQ - Somatic Symptoms)
Time frame: 6 weeks + one-month follow-up
Changes from baseline on the Multifactorial Memory Questionnaire (MMQ)
Time frame: 6 weeks + one-month follow-up
Changes from baseline in resting-state EEG
Time frame: 6 weeks + one-month follow-up
Changes from baseline in WHO Quality of Life Questionnaire - BREF (WHOQOL-BREF)
Time frame: 6 weeks + one-month follow-up
Changes from baseline Patient Global Impression of Improvement (PGI-I)
Time frame: 6 weeks + one-month follow-up
Changes from baseline on the Monetary Choice Questionnaire (Delay Discounting)
Time frame: 6 weeks + one-month follow-up
Changes from baseline in blood biomarkers
Time frame: 6 weeks + one-month follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2025.
Related trials for Mild Neurocognitive Disorder
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Community-based Screening for Alzheimer's Disease
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton
Hamilton, Canada
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Brainsway H1-Coil Deep TMS System, Brainsway H4-Coil Deep TMS System and Brainsway H7-Coil Deep TMS System in people with Mild Neurocognitive Disorder, run by St. Joseph's Healthcare Hamilton at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility criteria 1: Protocol completion (time frame: 6 weeks). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2025.